NEUSOFT XIKANG HOLDINGS INC. (HK:9686)
:9686
Top Page
NEUSOFT XIKANG HOLDINGS INC.
(9686)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.87
▼(-3.00% Downside)
Action:ReiteratedDate:03/25/26
The score is held back primarily by contracting revenue, ongoing net losses, and meaningful leverage, despite improving operating cash flow. Technicals add limited support with negative MACD and the price still below longer-term moving averages. Valuation is also a drag because earnings are negative and no dividend yield is available.
Positive Factors
Improving cash generation
Operating cash flow turning positive and increasing into 2025 represents a durable shift in cash-generation capacity. Sustained positive OCF can fund working capital, reduce near-term refinancing needs, and provide a base for measured reinvestment or gradual deleveraging if management maintains cash discipline over multiple quarters.
Negative Factors
Contracting revenue
Two consecutive years of material revenue decline undermine operating leverage and make margin recovery harder. Continued top-line contraction reduces cash flow headroom, limits reinvestment ability and raises the bar for returning to sustainable profitability without a clear, lasting revenue inflection or new growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving cash generation
Operating cash flow turning positive and increasing into 2025 represents a durable shift in cash-generation capacity. Sustained positive OCF can fund working capital, reduce near-term refinancing needs, and provide a base for measured reinvestment or gradual deleveraging if management maintains cash discipline over multiple quarters.
Read all positive factors
NEUSOFT XIKANG HOLDINGS INC. (9686) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$707.18M
Dividend YieldN/A
Average Volume (3M)60.92K
Price to Earnings (P/E)―
Beta (1Y)0.27
Revenue GrowthN/A
EPS GrowthN/A
CountryHK
Employees855
SectorHealthcare
Sector Strength45
IndustrySoftware - Services
Share Statistics
EPS (TTM)0.01
Shares Outstanding841,876,830
10 Day Avg. Volume65,850
30 Day Avg. Volume60,916
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)2.17
Price to Sales (P/S)1.51
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
NEUSOFT XIKANG HOLDINGS INC. Business Overview & Revenue Model
Company Description
Xikang Cloud Hospital Holdings, Inc. engages in the development of a city-specific cloud hospital platform. It operates through the following segments: Cloud Hospital Platform Services, Internet Medical Services, Health Management Services, and Sm...
How the Company Makes Money
null...
NEUSOFT XIKANG HOLDINGS INC. Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
40
Negative
Cash Flow
55
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 500.89M | 452.13M | 501.50M | 537.72M | 687.41M | 614.30M |
| Gross Profit | 144.25M | 123.47M | 147.50M | 164.61M | 168.45M | 170.23M |
| EBITDA | -45.88M | -26.86M | -52.06M | -75.65M | -161.41M | -214.71M |
| Net Income | -72.38M | -37.92M | -83.05M | -154.65M | -241.97M | -296.54M |
Balance Sheet | ||||||
| Total Assets | 1.11B | 1.14B | 1.26B | 1.40B | 934.45M | 946.85M |
| Cash, Cash Equivalents and Short-Term Investments | 703.42M | 760.09M | 797.70M | 822.67M | 351.76M | 364.91M |
| Total Debt | 520.84M | 518.78M | 574.47M | 603.44M | 573.44M | 456.28M |
| Total Liabilities | 785.76M | 827.90M | 892.31M | 964.28M | 1.38B | 1.21B |
| Stockholders Equity | 322.38M | 313.54M | 363.31M | 428.14M | -451.98M | -274.55M |
Cash Flow | ||||||
| Free Cash Flow | 36.20M | 0.00 | 21.56M | -24.42M | -81.17M | -101.77M |
| Operating Cash Flow | 35.91M | 39.50M | 21.56M | -20.16M | -73.83M | -83.38M |
| Investing Cash Flow | -30.55M | -151.64M | 110.45M | -146.60M | -8.45M | -5.47M |
| Financing Cash Flow | -93.62M | -88.65M | -56.56M | 504.77M | 64.62M | 64.90M |
NEUSOFT XIKANG HOLDINGS INC. Technical Analysis
Negative
0.90
Price Trends
0.87
Negative
0.90
Negative
0.93
Negative
Market Momentum
>-0.01
Negative
43.26
Neutral
23.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9686, the sentiment is Negative. The current price of 0.9 is above the 20-day moving average (MA) of 0.85, above the 50-day MA of 0.87, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.26 is Neutral, neither overbought nor oversold. The STOCH value of 23.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9686.
NEUSOFT XIKANG HOLDINGS INC. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$21.54B | 14.57 | 24.01% | 0.63% | 13.58% | 24.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$5.46B | -110.24 | -2.28% | ― | -4.99% | 47.18% | |
44 Neutral | HK$707.18M | -17.95 | -21.11% | ― | ― | ― | |
44 Neutral | HK$547.05M | -2.91 | -16.83% | ― | 11.43% | 4.88% | |
43 Neutral | HK$3.69B | -218.71 | 0.22% | ― | -4.38% | ― | |
41 Neutral | HK$1.08B | -176.64 | -13.92% | ― | -32.17% | -1.20% |
* Healthcare Sector Average
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.84
0.14
20.00%
HK:2158
Yidu Tech, Inc.
5.12
0.15
3.02%
HK:2160
MicroPort CardioFlow Medtech Corp.
2.90
-0.90
-23.68%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.00
-0.90
-31.03%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
10.91
-0.09
-0.82%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
42.50
20.49
93.09%
NEUSOFT XIKANG HOLDINGS INC. Corporate Events
Xikang Cloud Hospital Narrows Losses as Home-Based Care Strategy Takes Hold
Mar 20, 2026
Xikang Cloud Hospital reported 2025 revenue of RMB464.1 million, down 7.4% year-on-year, with gross margin slipping to 27.3%. Despite the top-line decline, tighter receivables management, economies of scale in nursing services, and digital and AI-...
Xikang Cloud Hospital Reinvests US$15.4 Million in Low-Risk Structured Note for Cash Management
Mar 13, 2026
Xikang Cloud Hospital Holdings Inc. has reinvested US$15.41 million of idle proceeds and returns from a maturing wealth management product into a new one-year guaranteed structured note issued by Shenwan Hongyuan Financial Products. The note, a lo...
Xikang Cloud Hospital Sets March Board Meeting to Approve 2025 Results
Mar 10, 2026
Xikang Cloud Hospital Holdings Inc. has scheduled a board meeting for 20 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the public...
Xikang Cloud Hospital Flags Sharp Narrowing of 2025 Loss on Better Collections
Mar 2, 2026
Xikang Cloud Hospital Holdings Inc. has warned that its net loss for the year ending 31 December 2025 is expected to narrow by at least 46% from the RMB83.8 million loss recorded in 2024. The company also anticipates its adjusted net loss, excludi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.